At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company’s major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll. The result of the poll was 36,568,508 votes for; and 390,152 votes against. There were 2,245,474 abstentions or withheld votes.
Accordingly, the aggregate percentage shareholding in the capital of the Company held by the parties specified in the table below (and persons deemed to be acting in concert with them under the Rules) (together, the “Affected Parties”) may proportionally increase up to the maximum percentage specified below in the event of the issue by the Company of up to 17,000,000 new ordinary shares, US
Shareholding (Number) | Shareholding (%) | Potential Shareholding Following Share Issues (%) | |
23,730,864 ordinary shares | 23.89% | 29.56% | |
23,667,540 ordinary shares | 23.82% | 29.50% | |
Management Individuals (as defined in the Proxy Statement) | 3,086,261 ordinary shares | 3.11% | 4.07% |
The full text of the resolution (being Proposal 3) is set out in the Proxy Statement in respect of the AGM which is available at https://www.rvlpharma.com.
About
Investor and Media Relations for
T: 212-452-2793
E: lwilson@insitecony.com
Source:
2023 GlobeNewswire, Inc., source